NASDAQ OMX

SGI Awarded $27M Systems Contract with the Army Research Laboratory Defense Supercomputing Resource Center

Del

MILPITAS, Calif., 2016-11-01 00:46 CET (GLOBE NEWSWIRE) -- Today, SGI (NASDAQ:SGI), a global leader in high-performance solutions for compute, data analytics, and data management, announced that the United States Department of Defense (DoD) has selected SGI® ICE™ XA for two of its Army Research Laboratory Defense Supercomputing Resource Center (ARL DSRC) systems. The upgrades are part of a technology insertion, known as TI-16, for their High Performance Computing Modernization Program (HPCMP).

HPCMP delivers world-class commercial, high-end, high-performance computational capabilities to DoD’s Research, Development, Test and Evaluation (RDT&E) community through its five DoD Supercomputing Resource Centers (DSRCs).

With HPC technology, DoD scientists and engineers can utilize physics-based simulations to achieve better understanding of a variety of phenomena affecting national defense. The upgraded systems also allow quick data searches that are generated from field tests across a wide spectrum of military operations. Powerful supercomputers help with data quality, increasing situational awareness, and advancing soldier performance with live and virtual data analytics. The new SGI systems will be leveraged to scale algorithms, increase real-time experimental data processing and methods for live-virtual simulations.

The agreement for ARL DSRC system #1 values at $8.9 million, and ARL DSRC system #2 at $17.6 million.

SGI was also awarded four annual maintenance options over the next four years, allowing DoD to leverage its world-class professional services available 24/7. The work for both systems will be performed at Aberdeen Proving Ground, Maryland, with an estimated completion date of April 24, 2021. Army Corps of Engineers, Huntsville, Alabama, has been delegated contracting authority for these agreements.

Announcement Highlights

  • DoD has selected SGI to increase supercomputing power with two ARL DSRC systems
  • DoD’s investment in supercomputers helps with data quality, increasing situational awareness, and advancing soldier performance with live and virtual data analytics; it also allows DoD scientists and engineers to achieve a better understanding of a variety of phenomena affecting national defense
  • The upgraded SGI systems will help DoD scale algorithms, increase real-time experimental data processing and methods for live-virtual simulations

Technical Information

  • ARL DSRC system #1 will deploy SGI® ICE™ XA with quad node blade and E-Cell technology, utilizing the 22-core Intel® Xeon® processor E5-2699 v4 to achieve peak compute power
  • ARL DSRC system #1 will be comprised of 33,088 compute cores offering 1.16 Petaflops capability, a Mellanox Enhanced Data Rate (EDR) as a 1:1 non-blocking Fat-Tree with 3.4 PB usable storage based on SGI InfiniteStorage 5600i technology
  • ARL DSRC system #2 will deploy SGI® ICE™ XA comprised of 73,920 Intel® Xeon® processor E5-2698 v4 compute cores, offering 2.6 Petaflops capability, a Mellanox Enhanced Data Rate (EDR)-based 1:1 non-blocking Fat-Tree and 11.8 PB usable storage based on SGI InfiniteStorage 5600i technology

Supporting Quotes

"We’re excited to partner with SGI for our TI-16 DoD program, and have full confidence in the system’s ability to provide excellent performance," said Dr. Raju Namburu, director of ARL DSRC. “Choosing the right HPC partners is crucial, as we rely on supercomputing and large-scale analytics and predictive sciences to provide the competitive edge we need to maintain our position as the nation’s premier laboratory for land forces.”

"We believe that the two SGI systems will bring a unique capability to solve DoD's most challenging problems," said Thomas Kendall, technical director of ARL DSRC. "The combination of a non-blocking, fat-tree topology, based on the recently available 100 Gbps EDR technology and the newest server CPU technology will enable a wide range of applications to consistently achieve high levels of performance.”

"DoD’s annual, recurring investment in HPC is a testament to its belief in the power and strategic value of supercomputing,” said Jorge Titinger, president and CEO, SGI. “Expanding our partnership with ARL DSCR is the result of our record of exceptional HPC performance with previous DoD systems. We have had a healthy long-standing relationship with HPCMP over the last two decades, and we remain committed to delivering to DoD new innovative technology and the highest level of service and management. We look forward to continuing our partnership with one of the most important institutions in our nation.”

Suggested Tweets

  • Army Research Labs chooses @SGI_Corp #HPC system for latest HPCMP deployment @INTEL #supercomputer http://bit.ly/2e5Qtps
  • ARL uses @SGI_Corp #supercomputer to scale algorithms increase real-time experimental data processing and methods for live-virtual simulations #HPC http://bit.ly/2e5Qtps

About SGI
SGI is a global leader in high-performance solutions for compute, data analytics, and data management that enable customers to accelerate time to discovery, innovation, and profitability. Visit sgi.com (sgi.com/) for more information.

Connect with SGI on Twitter (@sgi_corp), YouTube (youtube.com/sgicorp), 
Facebook (facebook.com/sgiglobal) and LinkedIn (linkedin.com/company/sgi).

Grayling Public Relations: Crystal Yang | (415) 593-1188 | sgi@grayling.com
SGI Investor Relations Contact: Ben Liao | (669) 900-8090 | bliao@sgi.com

© 2016 Silicon Graphics International Corp. All rights reserved. SGI and the SGI logo are trademarks or registered trademarks of Silicon Graphics International Corp. or its subsidiaries in the United States and/or other countries. Intel and Xeon are trademarks or registered trademarks of Intel Corporation. All other product and service names mentioned are the trademarks of their respective companies.

Om NASDAQ OMX

NASDAQ OMX
NASDAQ OMX
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra NASDAQ OMX

Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra NASDAQ OMX

Payvision's annual report reveals cross-border ecommerce trends in 201719.10.2017 09:00Pressemelding

With online marketplaces and consumer technology leading the way for growth AMSTERDAM, The Netherlands, Oct. 19, 2017 (GLOBE NEWSWIRE) -- Payvision, global acquirer and data-driven omnichannel solutions provider, has published the findings of its fifth annual cross-border ecommerce research report, in collaboration with Juniper Research. The paper includes the results of a global survey of various industry players regarding the game-changers, the biggest challenges, the best practices for going cross-border, and much more. When compared to last year's findings, the report reveals a new and exciting context for global cross-border trade. The compound annual growth rate predicted for the next three years for cross-border ecommerce is now 17%, whereas it stands at just 12% for ecommerce overall. Also, over the past 12 months, merchants' attitudes towards cross-border ecommerce have become more positive, with 50% of respondents agreeing and 31% strongly

High Seizure Frequency in Children with Dravet Syndrome Negatively Impacts Quality of Life, New International Caregiver Survey Finds19.10.2017 08:00Pressemelding

Global survey of 584 caregivers of children, young adults and adults with Dravet illustrates the detrimental effect of debilitating, frequent seizures on quality of life and co-morbidities Results suggest a need for more effective antiepileptic treatments EMERYVILLE, Calif. and BREST, France, Oct. 19, 2017 (GLOBE NEWSWIRE) -- The Dravet Syndrome European Federation and Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, announced today the publication of the initial results from a landmark survey into the clinical, social and economic consequences of Dravet syndrome on children, young adults and their families in Developmental Medicine & Child Neurology [doi:10.1111/dmcn.13591]. This study was led by Lieven Lagae, M.D., Ph.D., Professor at the University of Leuven, Belgium, Head of the Pediatric Neurology Department and Director of the Childhood Epilepsy

XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with Onivyde® and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer18.10.2017 16:53Pressemelding

AUSTIN, Texas, Oct. 18, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today enrollment of the first patient into a Phase I single arm study evaluating the maximum tolerated dose of Onivyde® (Irinotecan liposome injection) and 5-fluorouracil/folinic acid in combination with MABp1 in a cohort of patients with advanced pancreatic adenocarcinoma and cachexia. The patient has begun treatment at Cedars-Sinai Medical Center under the care of Dr. Andrew Hendifar, the Study's Principle Investigator, Medical Oncology lead for the Gastrointestinal Disease Research Group and Co-Director of Pancreas Oncology at Cedars-Sinai. A total of 16 patients are expected to be enrolled in the study. Dr. Hendifar commented, "We are excited to enroll our first patient in this novel combinatorial therapy for the treatment of advanced pancreatic cancer and cachexia. This is the first attempt to add an anti-inflammatory therapy to standard chemotherapy in an effort to improve the performanc

Nasdaq and SGX Establish Collaborative Listings Agreement18.10.2017 15:42Pressemelding

NEW YORK and SINGAPORE, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Nasdaq Inc. (Nasdaq:NDAQ) and Singapore Exchange (SGX) today announced the signing of a collaborative agreement in a move to leverage their strengths as two of the leading listings venues in the U.S. and Asia respectively. The new agreement seeks to enhance the channels available for companies to access capital market funding and enhance their corporate profile in both markets. As part of this agreement, Nasdaq and SGX -- who also share a successful, long-term market technology relationship -- are currently exploring the demand among corporates for a concurrent or sequential listing on both exchanges. Nasdaq and SGX are committed to supporting companies that are interested in pursuing this route. "The business landscape today is borderless," said Loh Boon Chye, CEO, SGX. "Fast-growing Asian companies looking to tap the capital markets can choose to list on SGX on Asian home ground, and embark on a listing on Nasdaq

Colliers International Expands in Washington, D.C.18.10.2017 14:30Pressemelding

Acquisition of Beltway Real Estate Services Firm Strengthens Ongoing Commitment to the Region TORONTO and WASHINGTON, Oct.  18, 2017  (GLOBE NEWSWIRE) -- Leading global commercial real estate services firm Colliers International Group Inc. (NASDAQ:CIGI)(TSX:CIGI) announced today the acquisition of leading tenant representation advisory firm Serten Advisors. With its office in Tysons Corner, the firm serves global, national, and regional clients with a highly skilled and experienced team of professionals that have more than 100 years of combined experience. "This strategic acquisition positions Colliers to gain additional market share and win new business in the vibrant and competitive Suburban DC markets," said Marty Pupil, Colliers International President | U.S. Brokerage. "Adding Steve and Paul and the rest of their talented leadership team to our existing group of professionals in the region will further position Colliers as the commercial real estate services firm of

InSphero to Present Novel 3D Human Liver Fibrosis Model at Annual Liver Meeting® in Washington, DC18.10.2017 14:00Pressemelding

InSphero AG / InSphero to Present Novel 3D Human Liver Fibrosis Model at Annual Liver Meeting® in Washington, DC . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. New 3D InSight(TM) Human Liver Fibrosis Model represents a powerful tool for screening efficacy and safety of anti-fibrotic drugs in vitro. Schlieren, Switzerland, Oct. 18, 2017 (GLOBE NEWSWIRE) -- InSphero AG, the leading supplier of assay-ready 3D cell culture models for accelerating drug discovery and development, will present data characterizing and demonstrating the utility of its new 3D InSight(TM) Human Liver Fibrosis Model for screening efficacy of anti-fibrotic drugs.  The findings will be presented at oral and poster presentations this Friday at the annual meeting of the American Association for the Study of Liver Disease (AASLD) Conference in Washington, DC.  Anti-fibrotic therapi

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom